Publicaciones
Publicaciones:
44. Delgado-Ramírez M, López-Serrano AL, Rodríguez-Menchaca AA. Inhibition of Kv2.1 potassium channels by the antidepressant drug sertraline. Eur J Pharmacol. 2024 Mar 6;970:176487.
43. Meza U, Romero-Méndez C, Sánchez-Armáss S, Rodríguez-Menchaca AA. Role of rafts in neurological disorders. Neurologia (Engl Ed). 2023 Nov-Dec;38(9):671-680.
42. Delgado-Ramírez M, López-Serrano AL, Sánchez-Armass S, Meza U, Rodríguez-Menchaca AA. Crosstalk between cholesterol and PIP2 in the regulation of Kv7.2/Kv7.3 channels. Biol Chem. 2023 Aug 8;405(3):161-165.
41. Arreola J, López-Romero AE, Pérez-Cornejo P, Rodríguez-Menchaca AA. Phosphatidylinositol 4,5-Bisphosphate and Cholesterol Regulators of the Calcium-Activated Chloride Channels TMEM16A and TMEM16B. Adv Exp Med Biol. 2023;1422:279-304.
40. Morán-Zendejas, R., Rodríguez-Menchaca, A.A. The anti-tumor drug 2-hydroxyoleic acid regulates the oncogenic potassium channel Kv10.1. Beni-Suef Univ J Basic Appl Sci. 2023;12:15.
39. Hernández-Adame PL, Meza U, Rodríguez-Menchaca AA, Sánchez-Armass S, Ruiz-García J, Gomez E. Determination of the size of lipid rafts studied through single-molecule FRET simulations. Biophys J. 2021;120(11):2287-2295.
38. Marmolejo-Murillo LG, Aréchiga-Figueroa IA, Moreno-Galindo EG, Ferrer T, Zamora-Cárdenas R, Navarro-Polanco RA, Sánchez-Chapula JA, Rodríguez-Menchaca AA. Kir4.1/Kir5.1 channels possess strong intrinsic inward rectification determined by a voltage-dependent K+-flux gating mechanism. J Gen Physiol. 2021 May 3;153(5):e201912540.
37. Pacheco-Rojas DO, Delgado-Ramírez M, Villatoro-Gómez K, Moreno-Galindo EG, Rodríguez-Menchaca AA, Sánchez-Chapula JA, Ferrer T. Riluzole inhibits Kv4.2 channels acting on the closed and closed inactivated states. Eur J Pharmacol. 2021 Mar 17;899:174026.
36. Delgado-Ramírez M, Rodriguez-Leal FJ, Rodríguez-Menchaca AA, Moreno-Galindo EG, Sanchez-Chapula JA, Ferrer T. Inhibitory effect of terfenadine on Kir2.1 and Kir2.3 channels. Acta Pharm. 2021 Jun 1;71(2):317-324.
35. Morán-Zendejas R, Delgado-Ramírez M, Xu J, Valdés-Abadía B, Aréchiga-Figueroa IA, Cui M, Rodríguez-Menchaca AA. In vitro and in silico characterization of the inhibition of Kir4.1 channels by aminoglycoside antibiotics. Br J Pharmacol. 2020 Jul 29;177(19):4548–60.
34. López-Serrano AL, De Jesús-Pérez JJ, Zamora-Cárdenas R, et al. Voltage-induced structural modifications on M2 muscarinic receptor and their functional implications when interacting with the superagonist iperoxo. Biochem Pharmacol. 2020;177:113961.
33. Meza U, Delgado-Ramírez M, Romero-Méndez C, Sánchez-Armass S, Rodríguez-Menchaca AA. Functional marriage in plasma membrane: Critical cholesterol level-optimal protein activity. Br J Pharmacol. 2020;177(11):2456-2465.
32. Valdés-Abadía B, Morán-Zendejas R, Rangel-Flores JM, Rodríguez-Menchaca AA. Chloroquine inhibits tumor-related Kv10.1 channel and decreases migration of MDA-MB-231 breast cancer cells in vitro. Eur J Pharmacol. 2019;855:262-266.
31. Delgado-Ramírez M, Rodríguez-Menchaca AA. Cytoskeleton disruption affects Kv2.1 channel function and its modulation by PIP2. J Physiol Sci. 2019;69(3):513-521.
30. Delgado-Ramírez M, López-Izquierdo A, Rodríguez-Menchaca AA. Dual regulation of hEAG1 channels by phosphatidylinositol 4,5-bisphosphate. Biochem Biophys Res Commun. 2018;503(4):2531-2535.
29. Delgado-Ramírez M, Sánchez-Armass S, Meza U, Rodríguez-Menchaca AA. Regulation of Kv7.2/Kv7.3 channels by cholesterol: Relevance of an optimum plasma membrane cholesterol content. Biochim Biophys Acta Biomembr. 2018;1860(5):1242-1251.
28. Delgado-Ramírez M, De Jesús-Pérez JJ, Aréchiga-Figueroa IA, et al. Regulation of Kv2.1 channel inactivation by phosphatidylinositol 4,5-bisphosphate. Sci Rep. 2018;8(1):1769. Published 2018 Jan 29.
27. Aréchiga-Figueroa IA, Morán-Zendejas R, Delgado-Ramírez M, Rodríguez-Menchaca AA. Phytochemicals genistein and capsaicin modulate Kv2.1 channel gating. Pharmacol Rep. 2017;69(6):1145-1153.
26. Aréchiga-Figueroa IA, Marmolejo-Murillo LG, Cui M, et al. High-potency block of Kir4.1 channels by pentamidine: Molecular basis. Eur J Pharmacol. 2017;815:56-63.
25. Marmolejo-Murillo LG, Aréchiga-Figueroa IA, Cui M, et al. Inhibition of Kir4.1 potassium channels by quinacrine. Brain Res. 2017;1663:87-94.
24. Marmolejo-Murillo LG, Aréchiga-Figueroa IA, Moreno-Galindo EG, et al. Chloroquine blocks the Kir4.1 channels by an open-pore blocking mechanism. Eur J Pharmacol. 2017;800:40-47.
23. Cruz-Rangel S, De Jesús-Pérez JJ, Aréchiga-Figueroa IA, et al. Extracellular protons enable activation of the calcium-dependent chloride channel TMEM16A. J Physiol. 2017;595(5):1515-1531. doi:10.1113/JP273111
22. Contreras-Vite JA, Cruz-Rangel S, De Jesús-Pérez JJ, et al. Revealing the activation pathway for TMEM16A chloride channels from macroscopic currents and kinetic models. Pflugers Arch. 2016;468(7):1241-1257. doi:10.1007/s00424-016-1830-9
21. Delgado-Ramírez M, Morán-Zendejas R, Aréchiga-Figueroa IA, Toro-Castillo C, Ramírez-Martínez JF, Rodríguez-Menchaca AA. Modulation of the voltage-gated potassium channel Kv2.1 by the anti-tumor alkylphospholipid perifosine. Pharmacol Rep. 2016;68(2):457-461. doi:10.1016/j.pharep.2015.11.006
20. Rodríguez-Menchaca AA, Aréchiga-Figueroa IA, Sánchez-Chapula JA. The molecular basis of chloroethylclonidine block of inward rectifier (Kir2.1 and Kir4.1) K(+) channels. Pharmacol Rep. 2016;68(2):383-389. doi:10.1016/j.pharep.2015.10.005
19. Aréchiga-Figueroa IA, Delgado-Ramírez M, Morán-Zendejas R, Rodríguez-Menchaca AA. Modulation of Kv2.1 channels inactivation by curcumin. Pharmacol Rep. 2015;67(6):1273-1279.
18. Licon Y, Leandro D, Romero-Mendez C, Rodriguez-Menchaca AA, Sanchez-Armass S, Meza U. Inhibition of CaV2.3 channels by NK1 receptors is sensitive to membrane cholesterol but insensitive to caveolin-1. Pflugers Arch. 2015;467(8):1699-1709.
17. Rodriguez-Menchaca AA, Ferrer T, Navarro-Polanco RA, Sanchez-Chapula JA, Moreno-Galindo EG. Impact of the whole-cell patch-clamp configuration on the pharmacological assessment of the hERG channel: trazodone as a case example. J Pharmacol Toxicol Methods. 2014;69(3):237-244.
16. Rodríguez-Menchaca AA, Adney SK, Zhou L, Logothetis DE. Dual Regulation of Voltage-Sensitive Ion Channels by PIP(2). Front Pharmacol. 2012;3:170. Published 2012 Sep 25.
15. Rosenhouse-Dantsker A, Noskov S, Han H, et al. Distant cytosolic residues mediate a two-way molecular switch that controls the modulation of inwardly rectifying potassium (Kir) channels by cholesterol and phosphatidylinositol 4,5-bisphosphate (PI(4,5)P(2)). J Biol Chem. 2012;287(48):40266-40278.
14. Rodriguez-Menchaca AA, Adney SK, Tang QY, et al. PIP2 controls voltage-sensor movement and pore opening of Kv channels through the S4-S5 linker. Proc Natl Acad Sci U S A. 2012;109(36):E2399-E2408.
13. Ponce-Balbuena D, Rodríguez-Menchaca AA, López-Izquierdo A, et al. Molecular mechanisms of chloroquine inhibition of heterologously expressed Kir6.2/SUR2A channels. Mol Pharmacol. 2012;82(5):803-813.
12. Deng W, Bukiya AN, Rodríguez-Menchaca AA, et al. Hypercholesterolemia induces up-regulation of KACh cardiac currents via a mechanism independent of phosphatidylinositol 4,5-bisphosphate and Gβγ. J Biol Chem. 2012;287(7):4925-4935.
11. Rodriguez-Menchaca AA, Solis E Jr, Cameron K, De Felice LJ. S(+)amphetamine induces a persistent leak in the human dopamine transporter: molecular stent hypothesis. Br J Pharmacol. 2012;165(8):2749-2757.
10. López-Izquierdo A, Aréchiga-Figueroa IA, Moreno-Galindo EG, et al. Mechanisms for Kir channel inhibition by quinacrine: acute pore block of Kir2.x channels and interference in PIP2 interaction with Kir2.x and Kir6.2 channels. Pflugers Arch. 2011;462(4):505-517.
09. López-Izquierdo A, Ponce-Balbuena D, Moreno-Galindo EG, et al. The antimalarial drug mefloquine inhibits cardiac inward rectifier K+ channels: evidence for interference in PIP2-channel interaction. J Cardiovasc Pharmacol. 2011;57(4):407-415.
08. López-Izquierdo A, Ponce-Balbuena D, Ferrer T, Rodríguez-Menchaca AA, Sánchez-Chapula JA. Thiopental inhibits function of different inward rectifying potassium channel isoforms by a similar mechanism. Eur J Pharmacol. 2010;638(1-3):33-41.
07. Ponce-Balbuena D, López-Izquierdo A, Ferrer T, Rodríguez-Menchaca AA, Aréchiga-Figueroa IA, Sánchez-Chapula JA. Tamoxifen inhibits inward rectifier K+ 2.x family of inward rectifier channels by interfering with phosphatidylinositol 4,5-bisphosphate-channel interactions. J Pharmacol Exp Ther. 2009;331(2):563-573.
06. Aréchiga IA, Barrio-Echavarria GF, Rodríguez-Menchaca AA, et al. Kv1.5 open channel block by the antiarrhythmic drug disopyramide: molecular determinants of block. J Pharmacol Sci. 2008;108(1):49-55.
05. Rosenhouse-Dantsker A, Sui JL, Zhao Q, et al. A sodium-mediated structural switch that controls the sensitivity of Kir channels to PtdIns(4,5)P(2). Nat Chem Biol. 2008;4(10):624-631.
04. Rodríguez-Menchaca AA, Navarro-Polanco RA, Ferrer-Villada T, et al. The molecular basis of chloroquine block of the inward rectifier Kir2.1 channel. Proc Natl Acad Sci U S A. 2008;105(4):1364-1368.
03. Torres-Jácome J, Tejeda-Chávez HR, Rodríguez-Menchaca AA, Sánchez-Chapula JA, Navarro-Polanco RA. The D3-dopaminergic agonist 7-hydroxy-dipropylaminotetralin (7-OH-DPAT) increases cardiac action potential duration and blocks human ether-a-go-go-related gene K+ channel. J Cardiovasc Pharmacol. 2006;47(5):656-662.
02. Rodriguez-Menchaca A, Ferrer-Villada T, Lara J, Fernandez D, Navarro-Polanco RA, Sanchez-Chapula JA. Block of HERG channels by berberine: mechanisms of voltage- and state-dependence probed with site-directed mutant channels. J Cardiovasc Pharmacol. 2006;47(1):21-29.
01. Ferrer-Villada T, Navarro-Polanco RA, Rodríguez-Menchaca AA, Benavides-Haro DE, Sánchez-Chapula JA. Inhibition of cardiac HERG potassium channels by antidepressant maprotiline. Eur J Pharmacol. 2006;531(1-3):1-8.